A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants

There remains a clear need for effective tumor cell purging in autologous stem cell transplantation (ASCT) where residual malignant cells within the autograft contribute to disease relapse. Here we propose the use of a novel Fas agonist with potent pro-apoptotic activity, termed MegaFasL, as an effe...

Full description

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2011-12, Vol.1 (12), p.e47-e47
Main Authors: Nahimana, A, Aubry, D, Lagopoulos, L, Greaney, P, Attinger, A, Demotz, S, Dawson, K M, Schapira, M, Tschopp, J, Dupuis, M, Duchosal, M A
Format: Article
Language:English
Subjects:
631/92/436/2388
692/699/67/1990
692/700/565/545/576/1855
Biomedical and Life Sciences
Biomedicine
Cancer Research
Hematology
Oncology
Original
original-article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There remains a clear need for effective tumor cell purging in autologous stem cell transplantation (ASCT) where residual malignant cells within the autograft contribute to disease relapse. Here we propose the use of a novel Fas agonist with potent pro-apoptotic activity, termed MegaFasL, as an effective ex-vivo purging agent. MegaFasL selectively kills hematological cancer cells from lymphomas and leukemias and prevents tumor development at concentrations that do not reduce the functional capacity of human hematopoietic stem/progenitor cells both in in vitro and in in vivo transplantation models. These findings highlight the potential use of MegaFasL as an ex-vivo purging agent in ASCT.
ISSN:2044-5385
2044-5385
DOI:10.1038/bcj.2011.47